Plasma amyloid beta X-42/X-40 ratio and cognitive decline in suspected early and preclinical Alzheimer's disease.
Alzheimer's & dementia : the journal of the Alzheimer's Association
View this publicationMember
My group has focused on fluid biomarkers for the detection of different neurodegenerative diseases, such as Alzheimer’s and Parkinson’s disease, Frontotemporal Dementia and Amyotrophic Lateral Sclerosis, especially in early, preclinical disease stages. In particular, we are interested in extracellular vesicles, not only as biomarkers but also as modulators of inflammation, their role in cell-cell communication and as potential carriers of disease pathology in neurodegeneration. We are employing data and biomaterial from patient cohorts as well as cell culture and murine models to elucidate the contribution of microglia to disease pathology in Alzheimer’s and Parkinson’s disease.
Alzheimer's & dementia : the journal of the Alzheimer's Association
View this publicationNature medicine
View this publicationJournal of Alzheimer's disease : JAD
View this publication